Tg Therapeutics (TGTX) Operating Income (2016 - 2025)
Historic Operating Income for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $29.4 million.
- Tg Therapeutics' Operating Income rose 13616.7% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 2045227.72%. This contributed to the annual value of $41.9 million for FY2024, which is 10321.33% up from last year.
- Per Tg Therapeutics' latest filing, its Operating Income stood at $29.4 million for Q3 2025, which was up 13616.7% from $34.8 million recorded in Q2 2025.
- Tg Therapeutics' Operating Income's 5-year high stood at $114.8 million during Q3 2023, with a 5-year trough of -$92.9 million in Q4 2021.
- Its 5-year average for Operating Income is -$22.5 million, with a median of -$35.0 million in 2022.
- As far as peak fluctuations go, Tg Therapeutics' Operating Income skyrocketed by 42830.13% in 2023, and later plummeted by 8916.75% in 2024.
- Tg Therapeutics' Operating Income (Quarter) stood at -$92.9 million in 2021, then increased by 16.58% to -$77.5 million in 2022, then surged by 83.9% to -$12.5 million in 2023, then skyrocketed by 339.88% to $29.9 million in 2024, then decreased by 1.95% to $29.4 million in 2025.
- Its Operating Income stands at $29.4 million for Q3 2025, versus $34.8 million for Q2 2025 and $8.6 million for Q1 2025.